Provided by Tiger Trade Technology Pte. Ltd.

GRAIL, Inc.

80.52
+5.417.20%
Volume:617.76K
Turnover:49.10M
Market Cap:3.60B
PE:-8.26
High:81.76
Open:75.67
Low:75.33
Close:75.11
52wk High:118.84
52wk Low:36.98
Shares:44.67M
Float Shares:40.64M
Volume Ratio:1.32
T/O Rate:1.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-9.7487
EPS(LYR):-11.1105
ROE:-16.12%
ROA:-12.03%
PB:1.41
PE(LYR):-7.25

Loading ...

Piper Sandler Remains a Hold on GRAIL Inc (GRAL)

TIPRANKS
·
Jun 02

Grail assumed with a Peer Perform at Wolfe Research

TIPRANKS
·
Jun 02

Sector Update: Healthcare Stocks Fall in Afternoon Trading

MT Newswires Live
·
Jun 02

BUZZ-U.S. STOCKS ON THE MOVE-Grail, Kohl, Virgin Galactic

Reuters
·
Jun 02

Grail falls -18.4%

TIPRANKS
·
Jun 02

BUZZ-Grail shares fall after large cancer blood test data yields mixed results

Reuters
·
Jun 02

Grail posts ASCO presentation on private-practice adoption of multi-cancer early detection test

Reuters
·
Jun 01

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday as AI Optimism Overshadows Middle East Risks

MT Newswires Live
·
Jun 01

GRAIL Shares Fall Pre-Bell After Galleri Trial Misses Primary Endpoint

MT Newswires Live
·
Jun 01

Canaccord Genuity Keeps Their Buy Rating on GRAIL Inc (GRAL)

TIPRANKS
·
Jun 01

Grail's Galleri Test Improves Cancer Detection in Pathfinder 2 Trial

MT Newswires Live
·
Jun 01

Grail presents ‘positive’ performance, safety results from Pathfinder 2 study

TIPRANKS
·
Jun 01

Grail reports results from NHS-Galleri trial in presentation at ASCO meeting

TIPRANKS
·
Jun 01

Grail Presents Pathfinder 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 Asco Annual Meeting

THOMSON REUTERS
·
May 31

BRIEF-Grail Reports Full Results From Nhs-Galleri Trial Demonstrating Substantial Reduction In Stage Iv Cancer Diagnoses

Reuters
·
May 30

Grail - Galleri Blood Test Reduces Stage Iv Diagnoses by 22% in Second and 26% in Third Rounds

THOMSON REUTERS
·
May 30

Grail Reports Full Results From Nhs-Galleri Trial Demonstrating Substantial Reduction in Stage Iv Cancer Diagnoses at 2026 Asco Annual Meeting

THOMSON REUTERS
·
May 30

Grail Inc - No Reduction Observed in Combined Primary Endpoint of Stage Iii/Iv Cancers in Aggregate

THOMSON REUTERS
·
May 30

Grail grants 34,350 RSUs to 56 new hires under inducement equity plan

Reuters
·
May 28

Grail Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 28